Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

experience delays in the conduct or completion of the PROPEL trial, whether caused by competition, adverse events, patient enrollment rates, regulatory issues or other factors; that clinical trials may not demonstrate that PDX is both safe and effective for the treatment of patients with PTCL or any other type of cancer; that data from preclinical studies and clinical trials may not be indicative of future clinical trial results; that the safety and/or efficacy results of the PROPEL trial may not support an application for marketing approval in the United States or any other country; that an application for marketing approval may not be accepted for priority review or at all by the FDA or any other regulatory authority; and that the Company may lack the financial resources and access to capital to fund future clinical trials for PDX or any of its other product candidates. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

Note: The Allos logo is a trademark of Allos Therapeutics, Inc.


'/>"/>
SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
(Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
... Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader ... Tech International (PTI), a joint venture of its subsidiary ... sales agreement with Cure Hands, a company of international ... agreement, Pharma Tech International, the exclusive distributor of CellerateRX® ...
... May 16, 2011 UBM Canon,s medical device publishing ... for the remainder of 2011. (Logo: ... an exciting list of comprehensive content topics that encompass ... outsourcing," stated Rich Nass, Director of Content for the ...
Cached Medicine Technology:International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 2International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 3International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 4UBM Canon Medical Device Content Team Announces Upcoming Virtual Event Content Topics 2UBM Canon Medical Device Content Team Announces Upcoming Virtual Event Content Topics 3
(Date:7/11/2014)... Obese and overweight firefighters are not receiving weight ... to new research from The University of Texas ... guidelines state that health care professionals (HCPs) should ... healthy weight. Firefighters have high rates of obesity, ... line-of-duty deaths in firefighters. This study assessed the ...
(Date:7/11/2014)... NY (PRWEB) July 11, 2014 The ... the five years to 2014 on the heels of ... 2010 prompted farmers to dedicate a larger share of ... production. More specifically, the regulations required the mixing of ... expanding biofuel production in the United States created a ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... from the worldwide scourge of dengue fever was somewhat successful ... only prevented dengue fever in 56 percent of the 10,000 ... protected more than 88 percent of them from severe disease. ... and sometimes death. "This vaccine has already proven to ...
(Date:7/11/2014)... July 11, 2014 Ticket Down is a reliable ... in Mountain View, CA. Over the years Luke Bryan has ... Not only does he do well at award shows, but each ... the most anticipated tours of the genre and this summer is ... artists can compare to the popularity and success that is currently ...
(Date:7/11/2014)... Riverside Health System became the first provider of ... late 2012 and now, in partnership with Williamsburg Landing, will ... Williamsburg and Newport News region. , Also known as life ... independent older adults who wish to remain in their homes ... continuing care services as well as control over the cost ...
Breaking Medicine News(10 mins):Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... New Survey Indicates that a Patient,s or Loved One,s Hearing ... to Inefficiency and ... Hearing loss among those,who require the assistance of a caregiver ... providing care, according to a new survey,released by Songbird Hearing, ...
... Winners Can Receive Up to $15,000 Each to Donate to Nonprofit of Their ... ... The deadline to submit,nominations for this year,s Welcome Back Awards, a national awards ... are now due by Monday, December 15, 2008., The Welcome Back Awards ...
... Calif., Nov. 12 Forterus,Inc. (OTC Bulletin Board: FTER) ... back up to $20,000 in stock in open market,transactions., ... is severely,undervalued, and does not reflect the financial success ... past two months," said,Paul Howarth, CEO of Forterus., ...
... Study Links Quercetin To Reduced Risk for Respiratory Infection, ... for a natural,way to stay well this cold and ... of today,s hottest "Super Fruits." In conjunction with,the typical ... known for its natural anti-viral activity and found in ...
... Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical company ... diseases,reported corporate and clinical program updates for the ... The updates were given during,a podium presentation by ... web,cast at the Rodman & Renshaw 10th Annual ...
... of the Place They Live , ... Alpharetta, Ga. (Vocus) November 12, ... headquarters on October 17, 2008. The building houses the six operating ... Associates had significant input into the design of the building from ...
Cached Medicine News:Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 2Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 3Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 4Health News:Deadline Extended to Submit Nominations for Depression Awards Program 2Health News:Deadline Extended to Submit Nominations for Depression Awards Program 3Health News:Forterus Inc. Announces Stock Buyback 2Health News:New Research Shows Specific Antioxidant, Found in Cherries, May Boost the Body's Defenses Against the Flu 2Health News:EntreMed Reports Clinical Program Progress and Company Update 2Health News:EntreMed Reports Clinical Program Progress and Company Update 3Health News:EntreMed Reports Clinical Program Progress and Company Update 4Health News:EntreMed Reports Clinical Program Progress and Company Update 5Health News:Jackson Healthcare Dedicates New Corporate Headquarters 2Health News:Jackson Healthcare Dedicates New Corporate Headquarters 3
... The Xact stent is self-expanding and has ... yet highly flexible mesh intended to help restore ... a smooth inner vessel surface, and potentially reduce ... diseased vessel when it is treated, which can ...
... Super Premium ALPHA 10 System offers ... in an intuitive and ergonomically designed ... ideal system for Perinatology/Maternal & Fetal ... Applications, Breast Imaging, and General Imaging ...
... (hGH; somatotropin) is a 22 kD, 191 amino ... of the anterior pituitary. The hGH gene contains ... five members of a gene family. The hGH ... of hGH released into the cell culture supernatant ...
... is the sulfate ester of DHEA, derived ... of DHEA in adrenal and extradrenal tissues. ... by the adrenal cortex, and is a ... possesses relatively weak androgenic activity, which for ...
Medicine Products: